Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin

The global prevalence of type 2 diabetes (T2D) is expected to exceed 642 million people by 2040. Metformin is a widely used biguanide T2D therapy, associated with rare but serious events of lactic acidosis, in particular with predisposing conditions (e.g., renal failure or major surgery). Imeglimin,...

Descripción completa

Detalles Bibliográficos
Autores principales: Theurey, Pierre, Vial, Guillaume, Fontaine, Eric, Monternier, Pierre‐Axel, Fouqueray, Pascale, Bolze, Sébastien, Moller, David E., Hallakou‐Bozec, Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915386/
https://www.ncbi.nlm.nih.gov/pubmed/35274817
http://dx.doi.org/10.14814/phy2.15151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915386/
https://www.ncbi.nlm.nih.gov/pubmed/35274817
http://dx.doi.org/10.14814/phy2.15151

Ejemplares similares